HeartSciences Inc. Net Assets
HeartSciences Inc. net assets. Based on the latest financial reports, HeartSciences Inc. (HSCS) has net assets worth $-2.03 Million USD as of July 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.74 Million) and total liabilities ($5.77 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of HeartSciences Inc. to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.03 Million |
| % of Total Assets | -54.4% |
| Annual Growth Rate | 199.2% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 47360.48 |
Net Assets of HeartSciences Inc. (2020–2026)
Net assets of HeartSciences Inc. from 2020 to 2026. This chart illustrates how HeartSciences Inc.'s net assets have evolved over time, based on quarterly financial data. See HeartSciences Inc. (HSCS) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for HeartSciences Inc. (2020–2026)
The table below shows the annual net assets of HeartSciences Inc. from 2020 to 2026. For live market cap and overall valuation, see HSCS market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2026-04-30 | $226.06 Million | +110081.26% |
| 2025-04-30 | $205.17K | -97.20% |
| 2024-04-30 | $7.32 Million | +3073.75% |
| 2023-04-30 | $230.56K | +103.81% |
| 2022-04-30 | $-6.06 Million | -217.13% |
| 2021-04-30 | $-1.91 Million | -705.16% |
| 2020-04-30 | $315.55K | -- |
Equity Component Analysis
This analysis shows how different components contribute to HeartSciences Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8522238752200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
HeartSciences Inc. Net Assets Breakdown (April 2026)
HeartSciences Inc. net assets breakdown by equity component as of April 2026.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.19 Million | 1.41% |
| Other Components | $85.49 Billion | 37907.59% |
| Total Equity | $225.53 Million | 100.00% |
HeartSciences Inc. Competitors by Market Cap
The table below lists competitors of HeartSciences Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Investsmart Group Ltd
AU:INV
|
$10.56 Million |
|
P3 Health Partners Inc
NASDAQ:PIII
|
$10.56 Million |
|
Xintela AB
ST:XINT
|
$10.60 Million |
|
Megapolitan Developments Tbk
JK:EMDE
|
$10.60 Million |
|
Ohmyhome Limited Ordinary Shares
NASDAQ:OMH
|
$10.56 Million |
|
Aksara Global Development Tbk PT
JK:GAMA
|
$10.56 Million |
|
Norben Tea & Exports Limited
NSE:NORBTEAEXP
|
$10.55 Million |
|
CADOGAN ENERGY SOLUTIONS
F:CPD
|
$10.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HeartSciences Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 205,171 to 225,527,000, a change of 225,321,829 (109821.5%).
- Net loss of 9,141,875 reduced equity.
- New share issuances of 5,722,046 increased equity.
- Other factors increased equity by 228,741,658.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.14 Million | -4.05% |
| Share Issuances | $5.72 Million | +2.54% |
| Other Changes | $228.74 Million | +101.43% |
| Total Change | $- | 109821.48% |
Book Value vs Market Value Analysis
This analysis compares HeartSciences Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.02x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.22x to 0.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-04-30 | $9.52 | $2.13 | x |
| 2021-04-30 | $-57.63 | $2.13 | x |
| 2022-04-30 | $-182.46 | $2.13 | x |
| 2023-04-30 | $2.90 | $2.13 | x |
| 2024-04-30 | $20.76 | $2.13 | x |
| 2025-04-30 | $0.22 | $2.13 | x |
| 2026-04-30 | $85.90 | $2.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HeartSciences Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -211666.47%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 23.34x
- Recent ROE (-4.05%) is above the historical average (-1190.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -1207.77% | -5937.99% | 0.03x | 6.20x | $-3.84 Million |
| 2021 | 0.00% | -9577.29% | 0.01x | 0.00x | $-2.26 Million |
| 2022 | 0.00% | -33592.57% | 0.01x | 0.00x | $-4.22 Million |
| 2023 | -2756.06% | -123384.27% | 0.00x | 14.26x | $-6.38 Million |
| 2024 | -90.27% | -35511.87% | 0.00x | 1.30x | $-7.34 Million |
| 2025 | -4272.16% | -201499.52% | 0.00x | 20.58x | $-8.79 Million |
| 2026 | -4.05% | -211666.47% | 0.00x | 23.34x | $-31.69 Million |
Industry Comparison
This section compares HeartSciences Inc.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $3,063,778,613
- Average return on equity (ROE) among peers: -67.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HeartSciences Inc. (HSCS) | $-2.03 Million | -1207.77% | N/A | $10.56 Million |
| Abbott Laboratories (ABT) | $30.72 Billion | 7.71% | 1.19x | $188.70 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $1.78 Million |
| Aethlon Medical Inc (AEMD) | $-713.05K | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-11.59 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.04 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $456.18K | -277.12% | 2.12x | $2.11 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $7.63 Million | -202.23% | 0.23x | $1.33 Million |
| Artivion Inc (AORT) | $48.34 Million | -66.81% | 0.55x | $931.88 Million |
| Apyx Medical Inc (APYX) | $22.89 Million | 2.69% | 0.23x | $118.37 Million |
About HeartSciences Inc.
HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related… Read more